OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Good to see the sp continuing to tick up slightly.
Hoping to read some articles about OXB in the
financial press over the weekend. A few articles
about takeover bids, liscening deals and OXB 'Buy'
recommendations would be nice.

Hopefully that will ensure the sp continues its
upward momentum next week ahead of the Trovax results
and preliminary results (possibly 3/03/05)

Sincere appologies for hogging this BB again.

Just clicked onto the Investors Chronicle
website (www.investorschronicle.co.uk/sections)

Under the company news section they have an
article titled
'Headache coming to an Endo for Vernalis'.

You've guessed it I'm not a subscriber. If anyone
reads the article and it mentions OXB please
share the comments here.

Thanks and good weekend to all.

1704 - I will check the IC this evening and post a summary.

Vernalis need the money to keep going - it would not be enough to buy OXB.

Thanks Pachandl!

Your wish is my command!
*********************************************
Headaches coming to an* Endo for Vernalis

Analysts are concerned that sales of Vernalis' migraine drug, Frovatriptan, have declined under new US marketing partner Endo.

Endo admitted this week* that fourth-quarter sales fell to $6.4m from $10m last year due to wholesaler destocking. However, the company says that until recently there has been *little active promotion but, with a new marketing campaign, prescriptions should pick up. Vernalis bought back the rights for Frovatriptan last year from Elan, relicensing it to Endo.


The sales decline is a** concern but approval of Frovatriptan for menstrually associated migraine could provide a boost. Fairly priced.
***********************************************

*****************************************

Cheers Fred - provides me with some extra drinking time.

Fred-Thanks for that much appreciated.

Penny Share Prophet renews its "speculative buy" rating for OXB. Nothing much added. Does not expect another bid (assumed it was Vernalis). Repeats expected news from Trovax trials, Prosavin entering trials, and confidence that "one big deal" will be pulled off this year.

thats all they need????????? lets hope they get there bid?

FROM TODAYS GUARDIAN


Traders said Oxford Biomedica, which called off merger talks earlier this month, will be one to watch next week. They believe the biotech company, spun out of Oxford University 10 years ago, is poised to make a positive announcement about its most advanced product, TroVax, which is in phase two trials. The stock closed unchanged at 20.75p.

Chaps

I feel this is going to be a fantastic week for all OXB holders. Going to get a few more first thing Monday morning. If the Trovax news is positive then there will be no holding her back.

27p plus..........imho

Midas7576-Agree with your recent post 100%. Hoping
to hear some postive news over the next 10 trading
days and to see the sp motoring upwards past 29p.

Pachandl- Forgot to thank you for sharing the information
found in the 'Penny Share Prophet' and 'The Guardian'
newspaper. I'm expecting some more positive articles
about OXB in the Financial Press over the next 2 weeks
and some large investors to start piling into the stock.

1704 - all part of the service! Will keep my eyes peeled for anything else. Stay lucky.

Thanks for the info, things are looking good.

Apple-Things are certainly looking good at the moment.

''Extra, Extra Read All About 'Share Price of OXB is going
to soar''

Independent Newspaper (Market Report: 1/03/05)by Michael Jikov

http://news.independent.co.uk

'OXB, 1p higher to 21.75p, was once again a talking
point among City gossips. Some suggested that the
biotech will before the end of the week unveil an
exciting licensing deal for one of its drugs,
possibly for its Trovax product. But others reckon
a fresh bid approach could soon be on the cards for OXB.
In January, shares in the group soared after it
admitted having recieved a takeover offer. At the time it
was widely rumoured that the offer had come from fellow
UK biotech Vernalis'.

Apple-Well done for calling the market correct last week
and getting in again at sub 20p.

MIDAS-Also seems to have called the market correctly with
a post he made a couple of weeks ago.

I just hope the results live up to the hype and we are
all celebrating (Fred and Pachandl included)in a few
days time.
Robstuff-Are you still around? Some comments from you
and other users of the BB would welcome
Queenie,Ethel,llwelyn,Oakapples etc)

All the Best

RNS stating that Man Financial Ltd have 6.03% of shares.

All sounds better and better.

Cheers, Madison

Madison-Thanks for your post.

Good news to hear that Man Financial
Ltd have increased their holdings. I have
been forecasting for the last few days that
I expect to see more large 'buys' coming
in from large institutions and private investors
over the next couple of weeks. I Expect to see
more announcements. My sp target of 35p by
the middle of March 05 may yet be achieved.

Go on OXB my son.

1704,

:-)
As for calling the market correct last week.

This is my favourite share because if you look back through this thread I nearly always seem to get this one right.

I can't claim that it is skill though because I don't seem to be calling it right quite so much on other shares.

I always keep a core holding on OXB though just in case I'm wrong when I see a peak.

I hope that they don't get taken over because then I won't be able to have anywhere near as much fun or profits as I do with this one.

In the long term, without a takeover, I see this being worth much more than we are likely to get from selling out to a bidder in the short term.

This is not just a 1 product company.

Trovax is likely to transform the share price but that is just the 1st of their portfolio of drugs & techniques.